Email updates

Keep up to date with the latest news and content from BMC Musculoskeletal Disorders and BioMed Central.

This article is part of the supplement: 6th European Symposium: Steps Forward in Pompe Disease

Open Access Poster presentation

Effects of exercise training in 23 adults with Pompe disease receiving enzyme therapy

Linda van den Berg1*, Marein Favejee12, Stephan Wens1, Michelle Kruijshaar1, Francois Karstens1, Robert Rozenberg2, Stephan Praet2, Arnold Reuser1, Pim Pijnappel1, Johannes Bussmann2, Pieter van Doorn1, Harm Kuipers3 and Ans van der Ploeg1

  • * Corresponding author: Linda van den Berg

Author Affiliations

1 Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, The Netherlands

2 Department of Rehabilitation Medicine & Physical Therapy, Erasmus MC University Medical Center, Rotterdam, The Netherlands

3 Department of Movement Sciences, School for Nutrition, Toxicology and Metabolism, Maastricht University, Maastricht, The Netherlands

For all author emails, please log on.

BMC Musculoskeletal Disorders 2013, 14(Suppl 2):P17  doi:10.1186/1471-2474-14-S2-P17

The electronic version of this article is the complete one and can be found online at:

Published:29 May 2013

© 2013 van den Berg et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Pompe disease is a metabolic myopathy caused by the deficiency of acid α-glucosidase. In addition to enzyme replacement therapy (ERT), exercise training may help improve patients’ fitness and physical functioning. Thus, we studied the safety and efficacy of exercise training in adult Pompe patients.


Inclusion criteria were:

1. ERT ≥ 1 year,

2. no walking aids,

3. no ventilators.

The 12-week training program consisted of aerobic, resistance, and core stability exercises in 36 sessions. Plasma creatine kinase (CK) was measured biweekly. Aerobic fitness, muscle strength, muscle function, core stability and body composition were evaluated before and after the program.


23 patients successfully completed the training program with no significant side-effects. Aerobic fitness improved, shown by increases in workload (100W ± 52 to 122W ± 53, p<0.01), maximal oxygen uptake (69.4% of normal ± 17.4 to 75.9% of normal ± 18.0, p<0.01), and anaerobic threshold (16.7 ± 4.3 ml/min/kg to 18.5 ± 4.7 ml/min/kg, p=0.01). Small increases were observed in total muscle strength and in proximal lower extremities using hand-held dynamometry (both p=0.01). This increase was mainly due to an eight percent-point increase in strength of the hip flexors (p<0.01). At the end of the program, timed muscle function tests indicated that patients took significantly less time to climb four stairs (0.3 second less, p=0.04) and rise from supine to standing (1 second less, p=0.03). The time to run 10 meters did not significantly change. The number of patients able to perform the core stability exercises rose during the training program, and the total time patients were able to remain in balance improved dramatically for all four positions (58% increase for the backbridge, 229% and 223% for the left and right side bridges, respectively, and 86% for the abdominal bridge; p<0.05). No changes in body composition were found.


This is the first study to prove that a combination of aerobic, strength and core stability training can be safely performed and leads to improvements in aerobic fitness, muscle strength, muscle function, and core stability in patients with Pompe disease receiving long-term ERT.